Speeple News Search

Sign Up! | Tags | Domains | Statistics | Options | Advanced Search

Altus shares nosedive despite Phase III success

fiercebiotech.com » 2008 » August » 12th » Altus shares nosedive despite Phase III success

Tagged: phase iii, altus pharmaceuticals, trizytek

Hitting a primary endpoint in a late-stage trial is not always a recipe for success, it seems. Shares of Altus Pharmaceuticals nosedived this morning after the company issued a release saying that its late-stage study of the cystic fibrosis drug Trizytek hit its primary endpoint in fat absorption. Trizytek is an enzyme replacement therapy. But the data evidently failed to completely satisfy all … Continue Reading »

Latest news from :

  1. J&J, Vanderbilt ink rich partnering deal
  2. Array biopharma cuts staff, seeks partnerships
  3. Merck, Galapagos ink $233M obesity deal
  4. Orexigen Phase III obesity drug meets endpoints
  5. Alnylam, Cubist form RNAi partnership

Latest news from fiercebiotech.com:

  1. India drawing more clinical trials
  2. Crucell shares soar on Wyeth merger talks
  3. Plexxikon, Roche ink $335M development pact
  4. Onyx forges $550M pact for S*Bio programs
  5. Satori gains $22M to push Alzheimer's work